Evidence map›Paper›PMID 41018607›Full record

ArticleACS omega2025

Resolving Hexose-Phosphates by LC-MS Leads to New Insights in PGM1-CDG Pathophysiology.

Karen Driesen, Sam De Craemer, Eva Morava, David Cassiman, Peter Witters, Bart Ghesquière

Abstract read
In one paragraph

Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Karen DriesenLaboratory of Applied Mass Spectrometry, Department of Cellular and Molecular Medicine, KU Leuven, Leuven 3000, Belgium.ORCID https://orcid.org/0000-0002-2153-1498
Sam De CraemerLaboratory of Applied Mass Spectrometry, Department of Cellular and Molecular Medicine, KU Leuven, Leuven 3000, Belgium.
Eva MoravaDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States.
David CassimanDepartment of Gastroenterology-Hepatology and Metabolic Center, University Hospital Leuven, 3000 Leuven, Belgium.
Peter WittersDepartment of Development and Regeneration, KU Leuven, 3000 Leuven, Belgium.
Bart GhesquièreLaboratory of Applied Mass Spectrometry, Department of Cellular and Molecular Medicine, KU Leuven, Leuven 3000, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hexose-phosphates play a role in many metabolic pathways, such as glycolysis and glycosylation. To understand the molecular basis of diseases such as congenital disorders of glycosylation (CDG), information about the source and abundance of hexose-phosphates is imperative. Mass spectrometry (MS)-based tracer metabolomics can provide this information, but hexose-phosphates are structural isomers with similar physicochemical properties, which makes them difficult to differentiate using MS. Here, we present and compare two optimized liquid-chromatography-based MS methods for the identification of relevant hexose-phosphates, compatible with tracer metabolomics. A combination of these two methods led to the analysis of eight hexose-monophosphates and two hexose-bisphosphates that can occur in humans. Both methods displayed linearity in 3 to 4 orders of magnitude, with limits of quantification between 0.5 and 50 nM, which is well within the cellular concentration range. The applicability of these methods to biological models was then proven in a study of the effect of galactose treatment in phosphoglucomutase 1 (PGM1)-CDG fibroblasts. Here, we show, for the first time, the hexose-phosphate profiles in CDG and how these change upon treatment.

Identifiers

PMID41018607
PMCPMC12461406

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.